Reserve Bank indicated for that application or to the offices of the Board of Governors. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Comments regarding this application must be received not later than April 2, 1987.

A. **Federal Reserve Bank of Chicago** (David S. Epstein, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *Republic Bancorp, Inc.*, Flint, Michigan; to acquire 100 percent of the voting shares of Republic Bank of Ann Arbor, Ann Arbor, Michigan, a *de novo* bank.

Board of Governors of the Federal Reserve System, March 9, 1987.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 87-5398 Filed 3-12-87; 8:45 am]

BILLING CODE 6210-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Agency Forms Submitted to the Office of Management and Budget for Clearance

Each Friday the Department of Health and Human Services (HHS) publishes a list of information collection packages it has submitted to the Office of Management and Budget (OMB) for clearance in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). The following are those packages submitted to OMB since the last list was published on March 6, 1987.

Public Health Service (PHS)

(Call Reports Clearance Officer on 202-245-2100 for copies of Package).

Food and Drug Administration

Subject: Anthelmintic Drug Products for OTC Human Use—Extension—(0910-0232)
Respondents: Businesses or other for-profit

Assistant Secretary for Health

Subject: Grant Applications for Minority Community Health Coalition Demonstration Projects—Reinstatement—(0937-0167)
Respondents: Non-profit institutions
OMB Desk Officer: Shannah Koss

Health Care Financing Administration (HCFA)

(Call Reports Clearance Officer on 301-594-8650 for copies of package).

Subject: Statistical Report on Medical Care: Eligibles, Recipients, Payments, and Services—Revision—(0938-0345)—HCFA-2082
Respondents: State or local governments
Subject: Information Collection Requirements in BPO-52-F, Identification of Third Party Liability Resources for Medical Assistance and State Plan Preprint—NEW—HCFA R-106 and HCFA-SP-2
Respondents: Individuals or households; State or local governments; Federal agencies or employees
Subject: Preclearance for: Evaluation of TEFRA HMO and CMP Program—NEW—HCFA-008
Respondents: Individuals or households; Businesses or other for-profit
Subject: Medicare Qualification Statement for Federal Employees—NEW—HCFA-565
Respondents: Individuals or households
Subject: Request for Enrollment in Supplementary Medical Insurance—Extension—(0938-0245) HCFA-4040
Respondents: Individuals or households
Subject: Revision to State Plan for Medicaid—State Plan revision for Qualifying Trust Funds and Pregnant Women—Revision—(0938-0193) HCFA-179
Respondents: State or local governments
OMB Desk Officer: Allison Herron

Social Security Administration (SSA)

(Call Reports Clearance Officer on 301-594-5706 for copies of package).

Subject: Claim for Amounts Due in the Case of a Deceased Beneficiary—Extension—(0960-0101)
Respondents: Individuals or households
Subject: Student's Statement Regarding School Attendance—Extension—(0960-0105)
Respondents: Individuals or households
Subject: Marriage Certification—Extension—(0960-0009)
Respondents: Individuals or households
Subject: Statement of Claimant or Other Person—Extension—(0960-0045)
Respondents: Individuals or households
Subject: Request for Withdrawal of Application—Extension—(0960-0015)
Respondents: Individuals or households
Subject: Federal Assistance—Revision—(0960-0184)
Respondents: Individuals or households; Businesses or other for-profit
Subject: Claimant's Medications—Extension—(0960-0289)
Respondents: Individuals or households
OMB Desk Officer: Judy Egan

Office of Human Development Services (OHDS)

(Call Reports Clearance Officer on 202-472-4415 for copies of package).

Subject: National Evaluation of the Impact of Guardians *AD Litem* in Child Abuse or Neglect Judicial Proceedings—NEW
Respondents: Individuals or households
OMB Desk Officer: Judy Egan

As mentioned above, copies of the information collection clearance packages can be obtained by calling the Reports Clearance Officer, on one of the following numbers:

HCFA: 301-594-8650
PHS/FDA: 202-245-2100
SSA: 301-594-5706
OHDS: 202-472-4415

Written comments and recommendations for the proposed information collections should be sent directly to the appropriate OMB Desk Officer designated above at the following address: OMB Reports Management Branch, New Executive Office Building, Room 3208, Washington, DC 20503, Attn: (name of OMB Desk Officer).

Dated: March 9, 1987.

James V. Oberthaler,

Deputy Assistant Secretary for Management Analysis and Systems.

[FR Doc. 87-5273 Filed 3-2-87; 8:45 am]

BILLING CODE 4150-04-M

Centers for Disease Control

Interagency Committee on Smoking and Health; Meeting

ACTION: Notice of meeting.

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (5 U.S.C. App. 2), the Centers for Disease Control announces the following Committee meeting.

Name: Interagency Committee on Smoking and Health.

Time and Date: 9 a.m.-4 p.m., March 31, 1987.

Place: Room 503-A, Hubert W. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201.

Status: Open.

Purpose: The Interagency Committee on Smoking and Health advises the Secretary, Department of Health and Human Services, and the Assistant Secretary for Health on: (a) Coordination of all research and education programs and other activities within the Department and with other Federal, State, local, and private agencies, and (b) establishment and maintenance of liaison with appropriate private entities, Federal agencies, and State and local public health

agencies with respect to smoking and health activities.

Agenda: The entire meeting will be open to the pulbic. It will include discussion of the smoking issue and its impact on minority populations. Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Substantive program information as well as summaries of the meeting and roster of Committee members may be obtained from: John Bagrosky, Executive Secretary, Interagency Committee on Smoking and Health Park Building, Room 1–10, 5600 Fishers Lane, Rockville, Maryland 20857, Telephones: FTS: 443–1575, Commercial: 301/443–1575.

Dated: March 9, 1987.

Robert L. Foster,

Assistant Director, Office of Program Support, Centers for Disease Control.

[FR Doc. 87–5394 Filed 3–12–87; 8:45 am]

BILLING CODE 4160–18–M

Food and Drug Administration

De Kalb Feeds, Inc.; Withdrawal of Approval of NADA's

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of two new animal drug applications (NADA's) held by De Kalb Feeds, Inc. One NADA provides for use of a Type A article containing 0.8 grams per pound tylosin for making Type C swine feeds and the other for a 10-gram-per-pound Type A article to make Type C swine, beef cattle, and chicken feeds. The firm requested the withdrawal of approvals.

EFFECTIVE DATE: March 23, 1987.

FOR FURTHER INFORMATION CONTACT: Mohammad I. Sharar, Center for Veterinary Medicine (HFV–214), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–3184.

SUPPLEMENTARY INFORMATION: De Kalb Feeds, Inc., P.O. Box 111, Rock Falls, IL 61071, is the sponsor of NADA 133–382 which provides for use of a 10-gram-per-pound tylosin Type A article to make Type C swine, beef cattle, and chicken feeds, and NADA 133–383 which provides for use of a 0.8-gram-per-pound tylosin Type A article to make Type C swine feeds. The NADA's were originally approved April 26, 1983 (48 FR 18801).

In a letter dated November 19, 1986, the sponsor requested the withdrawal of approvals because the products were not being manufactured.

Therefore, under the Federal Food, Drug, and Cosmetic Act (sec. 512(e), 82 Stat. 345–347 (21 U.S.C. 360b(e))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of both NADA 133–382 and 133–383 and all supplements thereto is hereby withdrawn, effective March 23, 1987.

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is removing those portions of the regulations that reflect these approvals and is removing the firm from the list of sponsors of approved NADA's.

Dated: March 9, 1987.

Gerald B. Guest,

Director, Center for Veterinary Medicine.

[FR Doc. 87–5448 Filed 3–12–87; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 87C–0023]

Cosmetic, Toiletry and Fragrance Association, Inc.; Filing of Color Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the Cosmetic, Toiletry and Fragrance Association, Inc., has filed a petition proposing that the color additive regulations be amended to provide for the safe use of carbon black for coloring cosmetics generally, including those for use in the area of the eye.

FOR FURTHER INFORMATION CONTACT: Blondell Anderson, Center for Food Safety and Applied Nutrition (HFF–334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–426–5487.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 706(d)(1), 74 Stat. 402–403 (21 U.S.C. 376(d)(1))), notice is given that a petition (CAP 7C0208) has been filed by the Cosmetic, Toiletry and Fragrance Association, Inc., 1110 Vermont Ave. NW., Washington, DC 20005, proposing that 21 CFR Part 74 of the color additive regulations be amended to provide for the safe use of carbon black as a color additive for coloring cosmetics generally, including cosmetics for use in the area of the eye.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: March 6, 1987.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 87–5384 Filed 3–12–87; 8:45 am]

BILLING CODE 4160–01–M

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

Meeting

The following advisory committee meeting is announced:

Board of Tea Experts

Date, time, and place. March 30 and 31, 10 a.m., Rm. 700, 850 Third Ave., Brooklyn, NY.

Type of meeting and contact person. Open public hearing, March 30, 10 a.m. to 11 a.m.; open committee discussion, 11 a.m. to 4:30 p.m.; open committee discussion, March 31, 10 a.m. to 4:30 p.m., Robert H. Dick, New York Regional Laboratory, Food and Drug Administration, 850 Third Ave., Brooklyn, NY 11232, 212–965–5739.

General function of the committee. The committee advises on establishment of uniform standards of purity, quality, and fitness for consumption of all teas imported into the United States under 21 U.S.C. 42.

Agenda—Open Public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

Open committee discussion. The committee will discuss and select tea standards.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee

meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (Subpart C of 21 CFR Part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR Part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

Persons interested in specific agenda items to be discussed in open session may ascertain from the contact person the approximate time of discussion.

A list of committee members and summary minutes of meetings may be requested from the Dockets Management Branch (HFA–305), Rm. 4–62, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under section 10(a) (1) and (2) of the Federal Advisory Committee Act (Pub. L. 92–463, 86 Stat. 770–776 (5 U.S.C. App. I)) and FDA's regulations (21 CFR Part 14) on advisory committees.

Dated: March 6, 1987.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 87–5385 Filed 3–12–87; 8:45 am]

BILLING CODE 4160–01–M

National Institutes of Health

National Cancer Institute; Notice of Establishment

Pursuant to the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92–463, 86, Stat. 770–776), and the Health Research Extension Act of 1985 (Pub. L. 99–158), the National Institutes of Health, announces the establishment by the Director, National Cancer Institute of the Acrylonitrile Study Advisory Panel and the Methylene Chloride Study Panel.

The Acrylonitrile Study Advisory Panel and the Methylene Chloride Study Advisory Panel shall advise the Director of the National Cancer Institute, Associate Director, Epidemiology and Biostatistics Program, and Director, Division of Cancer Etiology, NCI on various aspects of the epidemiology on the acrylonitrile and methylene chloride studies.

Authority for these Committees shall terminate on February 15, 1989, unless renewed by appropriate action as authorized by law.

Dated: March 9, 1987.

James B. Wyngaarden, M.D.,

Director, NIH.

[FR Doc. 87–5368 Filed 3–12–87; 8:45 am]

BILLING CODE 4140–01–M

Establishment of Advisory Council on Hazardous Substances Research and Training

Pursuant to the Federal Advisory Committee Act of October 6, 1972, (Pub. L. 92–463, 86 Stat. 770–776), and the Superfund Amendments and Reauthorization Act of 1986 (Pub. L. 99–499) the National Institutes of Health announces the establishment by the Secretary of Health and Human Services of the Advisory Council on Hazardous Substances Research and Training.

The Secretary of Health and Human Services is required under Section 311(a)(5) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, Pub. L. 96–510, as amended by the Superfund Amendments and Reauthorization Act of 1986, Pub. L. 99–499, to establish and support a hazardous substances research and training program. The Advisory Council shall advise the Secretary; the Assistant Secretary for Health; the Director, National Institutes of Health; and the Director, National Institute of Environmental Health Sciences, on the implementation of section 311(a) of the Act, and assist in the coordination of this subsection and other programs of research, demonstration and training under section 311 which are conducted or administered by the Environmental Protection Agency. The Council shall review the plan prepared by the Director of the National Institute of Environmental Health Sciences, review the report prepared by the Environmental Protection Agency and consult with the Department of Defense.

Subject to rechartering, the Advisory Council on Hazardous Substances Research and Training shall terminate on October 17, 1992.

Dated: March 9, 1987.

James B. Wyngaarden,

Director, NIH

[FR Doc. 87–5367 Filed 3–12–87; 8:45 am]

BILLING CODE 4140–01–M

Office of the Assistant Secretary for Health

National Center for Health Services Research and Health Care Technology Assessment; Assessment of the Cardiointegram, 1987

The Public Health Service (PHS), through the Office of Health Technology Assessment (OHTA), announces that it is seeking information in coordinating an assessment on the safety, clinical effectiveness and indications for the cardiointegram as a diagnostic and predictive cardiovascular test. Specifically this assessment seeks to determine whether or not the cardiointegram is useful as a sensitive or specific predictor of the presence or absence of coronary artery disease either when used as a screening or as a diagnostic test. Information that addresses the predictive value of the CIG as a diagnostic test is also being sought. Additionally, information is requested on whether the cardiointegram is an established and clinically accepted diagnostic modality, or is at present an investigational technique.

PHS assessments consist of a synthesis of information obtained from appropriate organizations in the private sector as well as from PHS agencies and others in the Federal Government. The